TREE NEWS update: Eli Lilly said its drug Foundayo is associated with a reduction in long-term predicted risk of type 2 diabetes and cardiovascular disease. The finding links the treatment to lower modeled risk scores for the two conditions over the long term. No further figures or trial details were disclosed.
Eli Lilly: Foundayo Linked to Lower Long-Term Predicted Risk of Type 2 Diabetes and Cardiovascular Disease
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
1m ago
HSBC Cuts 2026 and 2027 Gold Price Forecasts on Rate Hike, Oil Concerns
5m ago
North America Tech Software Index ETF Rises Over 1.1%, Steady Near Daily High of $108.28
10m ago
Trump Says Korea to Invest $20B in Alaska LNG; Lee Jae-myung Pushes Back
22m ago
Trump administration excludes key NATO allies from upcoming members’ meeting
31m ago
Kansas City Fed’s Schmid Says Officials Still Have Work to Do on Inflation
31m ago
Boston Fed’s Collins: US Economic Growth Near or Above Trend